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ABSTRACT
Uncontrolled cell proliferation, a hallmark of cancer, is associated with activation of CAD, a
multifunctional protein that catalyzes the first three steps in pyrimidine biosynthesis. The cell
cycle dependent regulation of pyrimidine biosynthesis is a consequence of sequential
phosphorylation of CAD Thr-456 and Ser-1406 by the MAP kinase and PKA cascades,
respectively. The mechanism that controls the timing of these events is not well understood.
Our hypothesis is that timing of the activation and nucleocytoplasmic dynamics of CAD is
controlled by signaling complexes with kinases and phosphatases. Interestingly, a consensus
sequence for PP1 targeting proteins is located immediately adjacent to Thr-456. Peptides were
synthesized corresponding to residues 444-460 of CAD that encompasses both the PP1
consensus sequence and Thr-456 as well as two mutant peptides in which Thr-456 was replaced
with Ala or Asp. The wild type peptide and Ala mutant were able to bind to PP1 while the Asp
mutant which, mimics phosphorylated CAD, does not.
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CHAPTER 1: INTRODUCTION
The Cell: The Fundamental Unit of Life
A cell is the structural and functional unit of all living organisms. It is the fundamental
unit in biology similar to an atom which occupies the center position in the physical science. A
cell carries out all the vital functions such as transport of nutrients, respiration, and reproduction.
Living organisms are divided as unicellular or multicellular. Multi-cellular organisms (Figure. 1)
show increasing complexity by allowing the differentiation of numerous cellular lineages with
specialized functions within the organism. Prokaryotes are usually single-celled organisms that
lack a cell nucleus, the most common examples of which are Escherichia coli and cyanobacteria,
the blue green algae. The cells of eukaryotes have a well-defined nucleus surrounded by a
nuclear membrane. Examples of eukaryotes include all plants and animal cells including
unicellular fungi (yeast, mold) and protozoans. The cell organelles have specialized functions
which are essential for growth and survival. The mitochondria metabolize energy; lipids and
glycoproteins are synthesized in the endoplasmic reticulum; lysosomes, present only in animal
cells, degrade worn out and dead cellular constituents; and chloroplasts, found in only plant cells,
carry out photosynthesis. The nucleus of the cell is the administrative headquarter because it
encloses the cell’s genome, i.e., the DNA (deoxyribonucleic acid) comprised of two helical
strands that are coiled around a common axis forming the double helix packaged within the
chromosomes. Living beings depend on genes, as they specify all proteins and functional RNA
chains. DNA and RNA are molecular precursors which store information and transmit this
information from one generation to the next which is the fundamental condition of life.

Figure 1. Prokaryotic and Eukaryotic cells1

The Eukaryotic Cell Cycle
A cell goes through many functional stages during its life cycle (Figure 2). It
undergoes cell division in need to replace worn out or dead cells. Whether the cell will
divide or not is a highly regulated process. For example, when a parent stem cell in the
bone marrow undergoes cell division to form two daughter cells, the daughter cells exit the
cell cycle and are differentiated to form
specialized blood cells that might
undergo apoptosis at a later time. When
a particular cell divides, new cells are
produced. After cell division, the two
daughter cells contain an identical set of
the parental cell’s genetic material. Cell
division is preceded by a replication
program that is largely executed by
Figure 2. Schematic representation of the
eukaryotic cell-cycle2
2

specific proteins. The cell cycle is a tightly programed and regulated mechanism in which
the initiation of specific stages occurs only after the successful completion of early ones
and the progress is tightly controlled by specific check points. Most eukaryotic cells
operate according to internal clocks via a highly regulated mechanism and proceed through
a sequence of cell- cycle phases during which DNA is duplicated during the synthesis (S)
phase and the copies are then distributed to opposite ends of the parent cell during the
mitotic (M) phase. Transition from one phase to the other is highly regulated at various
check points. The four phases in a eukaryotic cell cycle are G1, S, G2 and M. Interphase
comprises G1, S, and G2 phases. DNA is synthesized during the S phase and other
macromolecules are synthesized throughout the interphase. Whether a cell can grow and
divide is a highly controlled process at the cellular level.
Cancer is the second leading killer disease in the U.S and in a number of European
countries.3 In cancer, cell division is no longer restrained and cells continue to divide and
grow uncontrollably, forming malignant tumors, possibly invading nearby parts of the
body. In order to fully understand how a normal cell becomes cancerous, extensive
research efforts are devoted to intensely study the mechanism of cell division. A normal
cell converting into a cancerous one is a complex multi-step process involving various
factors such as genetic instability and increased DNA synthesis during the S-phase of the
cell cycle that requires an increased demand for pyrimidine and purine biosynthesis.
To understand how a normal cell might turn cancerous requires substantial analysis of the
proteome in both the normal and cancerous cells. Cancer can be considered as proteomic
disease since proteins have specific functions in cells and tissues and many are
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implicated to play critical roles in tumor genesis and influence the conversion of normal
cells into malignant ones. Currently, vast amounts of information are continuously
generated for proteomes of different types of cancer. Comparison of patterns of protein
expression in different types of cancers is anticipated to result in individualized therapy in
the long run. Proteomic techniques are largely used to investigate how signaling pathways
are altered in a way that may allow a normal cell to turn cancerous in the hopes of
identifying and ultimately developing new drugs that will improve our understanding of
how to target various signaling pathways to combat cancer.
In several types of cancer cells, key differences exist in the expression and/or
malfunction of certain proteins that regulate signaling cascades involved in, for example,
metabolism, DNA repair and cell-cycle regulation. Growth factors such as EGF (epidermal
growth factor) and PDGF (platelet derived growth factor) activate the mitogen activated
protein kinase (MAPK) cascade which is required for the proliferation of certain cells and
differentiation of others. However, uncontrolled activation of this pathway has been
implicated in cancer development.4 When one of the proteins in the pathway is mutated, it
can be constitutively stuck in the "on" or "off" position, which is a prerequisite for the
development of many cancers. Overexpression and malfunction of different proteins,
protein kinases and phosphatases and other components of the MAPK/ERK pathway are
believed to result in several types of cancer. A considerable number of drugs have been
developed that target particular components in this pathway. Many naturally occurring
toxins and pathogens can lead to mutations in particular protein kinases and phosphatases
that can result in a number of disorders due to altering the phosphorylation states of intracellular targets of many signaling cascades including the MAPK cascade.
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Overview: Phosphorylation
Phosphorylation is a ubiquitous cellular mechanism. In the early part of the 19th
century, the existence of phosphorylation was considered a biological method of merely
providing phosphorus as a nutrient and nothing more.5 All this changed in the late 1930s
when Carl and Getty Cori found that glycogen phosphorylase could be isolated in two
forms as phosphorylase b and phosphorylase a.4 A year later, Fischer and Krebs as well as
Wosilait and Sutherland found that the interconversion of phosphorylase b to
phosphorylase a involved a phosphorylation/dephosphorylation mechanism.4 This idea
was later shown to be true and has now become an integral example of cell biology and
signaling. It has been estimated that 30% of the proteins encoded by the human genome
contain covalently bound phosphate, and abnormal phosphorylation is now considered to
be a root cause of diseases such as cancer and other proliferative diseases.4 The extent of
phosphorylation of a protein is the result of a dynamic equilibrium between the activity of
protein kinases and protein phosphatases.
The addition of the phosphate group is catalyzed by enzymes known as kinases and
removal of phosphate groups is catalyzed by enzymes known as phosphatases (Figure 3).

Figure 3. Schematic representation of
phosphorylation/dephosphorylation by protein kinases
and protein phosphatases 6
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Phosphorylation predominantly
involves formation of a phosphoester of serine, threonine and
tyrosine –OH side chains and
sometimes phosphoramidate bonds
of histidine –NH side chains by the
transfer of the γ- phosphoryl group
of ATP (or sometimes GTP) to the –
OH group or –NH group in the side
chains of amino acid residues
(Figure 3).

Figure 4. Schematic representation of how
phosphorylation can cause conformational changes in a
protein 6

How Can Phosphorylation Control Enzyme Activity?
Protein phosphorylation is one type of post-translational modification. Since
phosphate groups are negatively charged, phosphorylation of proteins might alter its
overall charge which can then alter the conformation of the protein and ultimately its
functional activity and/or protein interacting partners (Figure 4). A change in the
phosphorylation state of a given protein can be due to change in the activities of either
protein kinase(s) or protein phosphatase(s). The activity of both protein kinases and protein
phosphatases is tightly regulated to allow the timely optimal functioning of the protein.
The activity of some protein kinases and protein phosphatases depends on the
concentration of second messengers such as cAMP, cGMP, Ca2+ or diacylglycerol.4 Other
protein kinases or phosphatases are membrane associated receptors (e.g., insulin receptor)
and are activated upon binding of their corresponding ligands.4 Signals from, for example,
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EGF and PDGF can activate protein kinases and phosphatases extracellularly. All signal
transduction pathways are regulated on some level by phosphorylation making
phosphorylation relevant to most, if not all areas of cell signaling. Upon reception of a
signal, these phosphorylation cascades continue to function until protein phosphatases are
activated and down-regulate the cascade. A typical outcome of phosphorylation in
response to a signal is activation of certain kinases and phosphatases which may then alter
the accessibility of binding sites on proteins for their binding and interacting partners,
altering their function.

Figure 5. Schematic representation of Phosphorylation
Cascade 6
Phosphorylation (Figure 5) is a molecular switch that directly turns on or off the functions
of proteins. Besides controlling enzyme activity and regulation, other functions include
regulating and controlling intracellular dynamics and interactions with other proteins or
peptides, or their possible degradation by proteases. With such mechanisms, the cell is
able to regulate a diverse set of processes including cellular movement, reproduction and
metabolism. The mammalian cell constantly receives signals from its surroundings to
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which it has to respond appropriately. Growth factors lead to growth of a cell, its
differentiation or proliferation. Defects in these tightly regulated and controlled processes
can cause cancer and chronic inflammatory diseases.4
Protein kinases and protein phosphatases are classified into three classes depending on
whether they act either on serine/threonine residues or on tyrosine residue or on all three
residues. A further classification is based on the structural relationship and enzymatic
properties of the catalytic subunits, subcellular localization, substrate specificity and/or the
sensitivity to specific activators and inhibitors.7
Protein Phosphatase 1:
Extensive research has been carried out in understanding the role of protein
serine/threonine phosphatases in control mechanisms in eukaryotes that regulates processes
as diverse as metabolic pathways, hormonal response and cellular signaling, gene
transcription, translation, cell division, learning and memory.8 The human genome
encodes ~ 500 kinases of which two thirds are serine/threonine kinases; thus, diversity of
kinases has kept pace with increasing complexity of organisms more so than protein
phosphatases. There are four distinct families of protein phosphatases which comprise ~
150 members, of which only 40 are serine/threonine phosphatases.7 The PTP family is
composed of protein tyrosine phosphatases and the dual-specificity protein phosphatases
which dephosphorylate phosphoserine and phosphothreonine as well as tyrosine residues.
Members of the PPM and FCP1 families are metal dependent protein serine /threonine
phosphatases. The PPM family includes the Mg2+ dependent PP2C enzymes while the
structurally unrelated FCP family has a single member, FCP1. All other
phosphoserine/phosphothreonine specific protein phosphatases belong to the PPP family
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which is further divided into sub-families PP1, PP2A (including PP4 and PP6), PP2B and
PP5. Protein phosphatase 1 (PP1) in particular is ubiquitously distributed and regulates a
broad range of cellular functions including glycogen metabolism, cell cycle progression
and muscle relaxation.9 PP1 has evolved to contain an efficient catalytic subunit but lacks
substrate specificity. The catalytic subunit of PP1 (PP1c) is highly conserved. PP1 is
37kDa major serine/threonine phosphatase that regulates a variety of cellular functions.
PP1 consists of a catalytic subunit and regulatory subunits that determine the subcellular
localization of PP1 and/or regulate its function. The PP1 inhibitory subunits are themselves
regulated by phosphorylation.
The PP1 catalytic subunit (PP1c) can form complexes with greater than 50 regulatory
subunits. The regulatory subunits that interact with PP1c control the specificity and
diversity of PP1 function.7 Most forms of regulation are achieved through the regulatory
subunits, although a small number of PP1c molecules may be inhibited by phosphorylation
during the cell cycle. Interaction of targeting subunits with PP1c modifies its substrate
specificity, most often by an allosteric mechanism.
A plethora of PP1 subunits have been identified and more than 50 regulatory subunits
have been discovered in higher eukaryotes.7 In eukaryotes multiple genes encode PP1c
isoforms.7 The four isoforms of mammalian PP1c are designated PP1α, PP1β (also known
as PP1δ) , PP1γ1 and PP1γ2, the latter two arising from alternative splicing.7 PP1α variant
PP1α2 is similar to the PP1α isoform that is predicted from the human genome sequence
(Ensembl, ENSP00000176139) indicating that alternative splicing gives rise to two α alpha
isoforms.7 Mammalian PP1c isoforms possess distinct tissue distribution and subcellular
localizations as shown in Figure 6.
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PP1 Holoenzymes
Cellular functions of protein phosphatase 1 are defined by the association of PP1
catalytic subunit with endogenous protein inhibitors and regulatory subunits. The PP1

Figure 6. Subcellular localization of PP1c isoforms. PP-1 isoforms are differentially
localized both during interphase and mitosis in HeLa cells. (A) Images for PP-1 α, γ1,
and δ (green) merged with respective images of propidium iodide counterstain (red) are
shown for cells at interphase and at mitotic metaphase.10

catalytic subunit forms complexes with more than 50 regulatory subunits in a mutually
exclusive manner of which a few are shown in Figure 7 and Table 1.
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Figure 7. Schematic representation of mammalian PP1 binding subunits.7

Table 1. PP1 regulatory subunits 8
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The major region of PP1c that interacts with regulatory subunits consists of 1) a
hydrophobic groove to which a RVXF motif binds, and 2) a neighboring negatively
charged region. Many PP1 regulators consist of a consensus RVXF sequence that docks
within the hydrophobic groove on the surface of the PP1 catalytic subunit. Site-directed
mutagenesis studies have narrowed down the consensus sequence for this motif as [RK]X0-1[VI]-{P}-[FW] where X is any residue except proline.11 While there are other binding
sites on many of the regulatory subunits for PP1, mutations of the RVXF sequence hinders
PP1 binding.12 Crystallization of a small region of a GM peptide with PP1c identified the
RVXF motif as the main sequence that mediates the interaction with a hydrophobic groove
on the surface of PP1c, that is distinct from the active site, that binds to the substrate and
the phosphorylated residues of inhibitor proteins. The hydrophobic RVXF-binding groove
is located near the C-terminus of PP1c and includes residues Ile169, Leu243, Phe257,
Leu289-Cys291 and Phe293, which interact mainly with valine and phenylalanine residues
in the GM peptide containing the RVXF motif.12 PP1C contains a negatively charged
region that accommodates basic residues preceding the RVXF motif.
The RVXF motif, found in about 100 PP1c-binding proteins, binds to a hydrophobic
surface groove located on a surface behind the PP1c active site. The RVXF binding
channel is a hydrophobic groove opposite the catalytic site and is formed by top and rear
edges of two central beta sheets. Binding via the RVXF motif does modify the
conformation of PP1 but does not significantly affect the catalytic activity. The available
data suggests that the RVXF motif serves as an anchor for the initial binding of the
regulatory units thereby promoting binding to secondary sites that often bind with lower
affinity but affect the overall activity and substrate specificity of PP1.12
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Figure 8. Structure of the PP1c–RVXF-containing- microcystin peptide complex. PP1c is shown
as a ribbon structure. The β12-β13 loop that covalently binds to microcystin is indicated in the
middle.7

The β-12 and β-13 loop form a flexible binding site of PP1 through which toxins, including
microcystin, and inhibitors such as Inhibitor-1, DARP-32 and Inhibitor-2 bind with PP1.13
The loop partially guards the entrance to the active site and undergoes conformational
changes upon binding to partners. The β-12 and β-13 loop contains Cys273 that covalently
binds to microcystin.
Inhibitor-2
The function of PP1 is largely determined by its associated regulatory subunits that
can direct the enzyme to various subcellular compartments to be in close proximity to its
substrates. Inhibitor-2 (I-2) was the first protein phosphatase inhibitor identified and
known to form a stable high affinity complex with PP1 with nanomolar affinity (Kd=2
M).14 Studies have shown that I-2 mediated inhibition of PP1 regulates cardiac
contractility.16 PP1-I2 complex also plays a role in other processes such as cell division.17
13

Figure 9. Ribbon structure PP1c-I2 complex. 14

I-2 associates with the PP1 catalytic subunit to form a complex that is subsequently
regulated by the phosphorylation of I-2. I-2 inhibits the PP1 free catalytic subunit and
controls the state of activation of PP1. The bound I-2 causes conformational changes
which are reversed upon phosphorylation of a conserved Thr (Thr-Pro) site on I-2.15 The
inactive complex can be reactivated through phosphorylation of I-2 at Thr72 by glycogen
synthase kinase-3 or the extracellular-regulated kinase 2 (ERK2).15
Different domains of I-2 are involved in inhibition, inactivation, and reactivation of
PP1. The first 35 residues on the N-terminus and more specifically the motif, 10–13
(IKGI) of I-2, play a role in inhibition.15 This motif of I-2 binds to a negatively charged
region close to the RVXF-binding groove. This region is similar to that known to bind
basic residues upstream of the RVXF motif in many PP1 targeting subunits. The region
encompassing Thr72 is involved in inactivation of PP1, whereas the COOH-terminal
region of I-2 is required for reactivation of the inactive complex.15
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Multiple regulatory subunits as well as inhibitor proteins besides I-2 compete for a binding
site on PP1c. It is proposed that PP1c binds only one protein at a time either to a regulatory
subunit or inhibitor proteins such as I-2.18
CAD
Over the past decades, extensive research has been carried out to better understand the
mechanisms by which signals are transmitted from cell surface receptors to intracellular targets.
Protein phosphorylation is a post-translational modification of proteins whereby a serine, a
threonine or a tyrosine residue is phosphorylated by a protein kinase by the addition of a
covalently bound phosphate group. Phosphorylation of proteins is one of the most common
modes of regulation of protein function and activity. Growth signals typically initiate receptormediated signal transduction cascades which involve reversible protein phosphorylation that
facilitates changes in, for example, transcriptional, translational and cell-cycle regulatory events.
Among the large number of proteins regulated by phosphorylation, several are key
enzymes in basic metabolic pathways including de novo nucleotide biosynthesis, for example
CAD, the key large mammalian multifunctional protein that catalyzes the first three steps in the
de novo pyrimidine biosynthetic pathway.19 Proliferating cells require increased amounts of
pyrimidine nucleotides for the synthesis of DNA, RNA, phospholipids, glycogen and other
biological molecules involved in various processes. CAD consists of six copies of a 243 kDa
polypeptide comprised of 2225 amino acid residues.19 The tri-functional polypeptide is organized
into discrete functional domains that carry glutamine-dependent carbamoyl phosphate synthetase
(CPSase), aspartate transcarbamoylase and dihydroorotase (DHOase) activities.19
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Figure10. The domain structure of the multifunctional protein CAD that catalyzes the first three
steps in de novo pyrimidine biosynthesis19

CAD is regulated by a number of different mechanisms including allosteric and
transcriptional regulation, phosphorylation and selective degradation. The activity of the protein
invariably increases in tumor cells to meet the increased demand for pyrimidines during
proliferation. The CAD complex is activated by MAP kinase (Erk1/2) just prior to the S phase of
the cell cycle, when DNA synthesis occurs. MAP kinase is an enzyme that phosphorylates
proteins involved in cell growth and division.20 Growth signals initiate a signaling cascade that
activates MAP kinase and leads to the phosphorylation of CAD on Thr-456 in the A1 subdomain
(Figure 10). Upon completion of DNA synthesis, the cells emerge from S phase, CAD is
dephosphorylated and a second kinase, protein kinase A (PKA), phosphorylates CAD at Ser1046 in the B3 subdomain leading to deactivation and a decreased flux through the de novo
pyrimidine biosynthetic pathway (Figure 11).20

16 19
Figure 11. Schematic representation of cell cycle regulation of de novo pyrimidine biosynthesis

The timing of the up and down regulation of CAD must be precise but the control
mechanisms that regulate the processes are not yet fully understood. Studies have shown that
phosphorylation of CAD by PKA down regulates the pathway.21 It has also been shown that
MAP kinase and PKA form stable complexes with CAD suggesting that mutual antagonism is
the result of steric effect by the bound kinases.22 The cytoplasmic level of CAD is higher in
resting cells and is primarily unphosphorylated.23 Cell fractionation and fluorescence microscopy
studies (Figure 12) showed that Thr (P)-456 CAD was primarily localized within the nucleus.23

Figure 12. Confocal microscopic images of intracellular localization of CAD. Dephosphorylated
is cytosolic whereas phosphorylated CAD P-Thr456 is nuclear22
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The rate of the de novo pyrimidine biosynthetic pathway was found to be up-regulated in
MCF7 breast cancer cells. The activity was 4.4 fold higher than the normal MCF10A breast
cells.23 The growth dependent changes in the CAD phosphorylation state and the associated
changes in the rate of pyrimidine biosynthesis are similar in normal breast cells MCF10A and
BHK21 cells but quite different in the highly malignant MCF7 cells.23 In MCF10A cells, the rate
of pyrimidine biosynthesis is low and CAD is dephosphorylated prior to S phase.23 As the
cultured cells enter the S phase, MAPK is activated and CAD-Thr456 is phosphorylated and
pyrimidine biosynthesis is up-regulated. As the cells become confluent, the activity of MAP
kinase decreases and CAD-Thr456 is dephosphorylated. Subsequently, CAD Ser1406 is
phosphorylated and pyrimidine biosynthesis is down regulated. In MCF7 cells, CAD-Thr456 is
persistently phosphorylated while Ser1406 is dephosphorylated leading to a constant rate in
pyrimidine biosynthesis.23 The activity of the pathway was high in newly passaged cells and
increased only slightly as the culture became confluent. It has been shown that there was no
down regulation of the pathway at higher cell densities.23 Thus, the cell cycle- dependent
regulation of pyrimidine biosynthesis is tightly regulated by reciprocal antagonism of CAD
phosphorylation by MAP kinase and PKA.23
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HYPOTHESIS
Why CAD and PP1?
This thesis project focused on the interaction between CAD and PP1. PP1 is known to
bind to many different targeting proteins. The sequence recognized by PP1 as the binding site of
a large number of targeting proteins is highly conserved, Lysine (or Arginine)-Valine-XPhenylalanine, RVXF or KVXF, where X is any amino acid except Proline as Proline causes
steric effects.11 There is only one such sequence in the CAD complex located immediately
adjacent to the MAP kinase site, Thr-456 (Figure 13).
Our working hypothesis is that phosphorylation of Thr-456 blocks the binding of PP1 and
thus prevents the premature dephosphorylation and down regulation of the pathway. At the end
of S phase, the phosphorylation of CAD by PKA alters the conformation of the protein allowing
dephosphorylation of Thr-456 by PP1.
The objectives of this project are to determine 1) the binding or docking site on CAD for
PP1 and 2) whether the binding of PP1 depends on whether or not Thr-456 is phosphorylated.
Accomplishing these two objectives is significant as it provides insight into the timing of
the phosphorylation/dephosphorylation events of CAD and the resulting outcome on pyrimidine
biosynthesis.

Consensus sequence: KVYF

Figure 13. Schematic representation of CAD, residues 1-2225, comprising the
putative PP1 binding sequence, KVXF
19

CHAPTER 2: EXPERIMENTAL METHODS
Several different methods were employed to address the objectives of the project.
Immunoprecipitation
Immunoprecipitation (Figure 14) was used to establish that a complex forms between
CAD and PP1. This experiment was carried out by my lab colleagues, Kyle Poulsen and David
McDiarmid in Dr. Evans’ Lab at Eastern Michigan University.

Figure 14. Schematic representation of immunoprecipitation 24

In this method, one of the proteins, for example, CAD is reacted with CAD-specific
antibodies and then incubated with beads that have high affinity for immunoglobins. The protein
bound to the bead is then reacted with a second antibody, for example, directed against PP1, to
determine whether it forms a complex with the CAD that was previously bound to the beads. The
immunoprecipitated proteins are analyzed by Western blotting.
The Microcystin pull down assay was performed by Frederic Sigoillot at Wayne State
University. Microcystins are hepatotoxic cyclic peptides produced by cyanobacteria (e.g.
Microcystis aeruginosa). Microcystins strongly inhibit protein phosphatases type 1 (PP1).
20

Pull down assays are in-vitro assays used to confirm the existence of protein-protein interactions
previously predicted by other research techniques such as immunoprecipitation (IP). The
working principle is similar to that of immunoprecipitation with the only difference being that a
tag is used, such as a histidine-tag, instead of an antibody.
Peptide Synthesis
In order to determine the location of the PP1 binding site on CAD, a 17 amino acid
residue peptide (residues 444-460) was synthesized in collaboration with Dr. Debbie Heyl-Clegg
which corresponded to the naturally occurring sequence in CAD.
Wild-Type peptide
444Gln-Gly-Leu-Ala-Asp-Lys-Val-Tyr-Phe-Leu-Pro-Lle-Thr-Pro-His-Tyr-Val460
Putative PP1 binding site

MAP kinase site

This peptide was used in competition experiments to determine whether it could bind to
PP1 and block the binding and effect of Inhibitor-2 (I-2) on PP1 catalytic activity. No sequence
analogous to the consensus RVXF motif is found in I-2. However, the fact that DARPP-32
peptide containing a KIQF is able to antagonize PP1 inhibition by I-2 suggests that I-2 contains a
similar sequence. Inhibition of PP1 was measured by assaying the hydrolysis of p-nitrophenyl
phosphate which produces a colored product that can be measured using a spectrophotometer.
Our hypothesis is that if the peptide binds to PP1, then it should result in blocking or
reducing PP1 inhibition by I-2. Moreover, to determine whether the phosphorylation state of
Thr456 influences the interaction of CAD with PP1, two additional peptides were synthesized. In
one, Thr456 was replaced with Alanine (Ala) as it cannot be phosphorylated.27 The second
peptide was synthesized replacing Thr-456 with Aspartate (Asp). Aspartate has been reported in
several studies to mimic a phosphorylated residue both in vitro and in vivo as when a protein is
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phosphorylated, a negative charge is added to the amino acid side chain that mimics that of
aspartate.28
Mutant peptide1
444Gln-Gly-Leu-Ala-Asp-Lys-Val-Tyr-Phe-Leu-Pro-Lle-Ala-Pro-His-Tyr-Val460
Mutant peptide 2
444Gln-Gly-Leu-Ala-Asp-Lys-Val-Tyr-Phe-Leu-Pro-Lle-Asp-Pro-His-Tyr-Val460
Solid Phase Peptide Synthesis
Solid phase synthesis is the most commonly used methodology to synthesize peptides.
The fundamental premise of this method is that amino acids are coupled in the desired sequence
followed by removal of reversible protecting groups while the C-terminal of the first amino acid
is anchored to an insoluble support, a resin. Double coupling was carried out in the chain
assembly in order to achieve better yields.
Solid phase peptide synthesis (Figure 15) involves repetition of two steps, coupling and
deprotection of amino acids assisted by various reagents. Wash steps remove impurities several
times during each cycle. Synthesis starts with the C-terminal amino acid of the sequence. The Cterminal amino acid is attached to a cross-linked polystyrene resin via an acid labile bond with a
linker molecule. The resin is placed in the reaction vessel and subsequently deprotected. The
desired amino acids are added one at time always at the C-terminus of the amino acid at the end
of the growing chain. The N-terminal α- amine group of the added amino acid is protected during
coupling and then deprotected awaiting the next amino acid to be added to it. Following this
pattern, the peptide is synthesized with amino acids added in order and then the N-terminus can
be capped with acetic anhydride to form an acetylated amine.
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Figure 15. Schematic representation of solid phase peptide synthesis 25

Three steps are repeated each time as shown in Figure 15:
1) Deprotection of the N-terminal amino acid of the peptide carried out by 20% piperidine
in DMF to remove the Fmoc (fluorenylmethyloxycarbonyl) group from the α-amine.
2) Activation and coupling of the next amino acid using HBTU (O-(Benzotriazol-1-yl)N,N,N',N'-tetramethyluronium hexafluorophosphate)
3) Deprotection of the N-terminus of the new amino acid and repetition until the desired
peptide is assembled on the resin. A biotin tag was further added at the N-terminus of the
three peptides.
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The Rainin PS3 synthesizer monitors the deprotection and coupling steps. At the end of
the synthesis, the peptide is cleaved from the resin and the side chain protection groups are then
removed from the peptide. This is achieved by using a mixture of 90% trifluoroacetic acid (TFA)
and scavengers (phenol, water, anisole) that result in solubilization of the peptide. The peptide is
then precipitated in cold diethyl ether, re-dissolved in water lyophilized and purified by RPHPLC.
Crude peptides were purified to homogeneity by preparative reversed-phase high
performance liquid chromatography (RP-HPLC) on a Waters instrument with a Phenomenex
Jupiter C18 column (2.2 x 25.0 cm, 10mL/min). A linear gradient of 105 acetonitrile (0.1%
TFA)/water (0.1%TFA) to 50% acetonitrile (0.1% TFA)/water (0.1%TFA) was employed,
followed by lyophilization. Peptide purity was assessed by analytical RP-HPLC. Peaks were
monitored at 214, 230, 254 and 280 nm. The peptides were >97% pure as analyzed by peak
integration. Electrospray mass spectrometry confirmed the appropriate molecular weights.
Protein Phosphatase Assay:
p-Nitrophenyl Phosphate (PNPP) is a non-specific, chromogenic substrate used to assay
(Figure 16) most phosphatases such as alkaline phosphatases, acid phosphatases, protein
tyrosine phosphatases and serine/threonine phosphatases. The PNPP phosphatase activity is a
spectrophotometric assay based on the ability of phosphatases to catalyze the hydrolysis of PNPP
to p-nitrophenol, a chromogenic product with absorbance at 405 nm. The reaction product, pnitrophenol, which is soluble under alkaline conditions, has an intense yellow color.
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Phosphatase

p-Nitrophenyl phosphate

p-Nitrophenol + phosphate

Figure16. The biochemical principle of the alkaline phosphatase assay. 26

The 1ml of the biotinylated peptides (concentration 1mg/ml, 567 µM) was dissolved in
50 µl DMSO prior to use. The total reaction mixture (50 µl) consisting of 5 µl 10X PP1 reaction
buffer, 5 µl of 10X MnCl2, 800 units (0.8 µl) I-2 and 1.25 units (0.5 µl) PP1 was incubated prior
to addition of the substrate PNPP (5 µl of 500mM PNPP, final concentration of 50mM and the
reaction was quenched by addition of 1 ml of 1N NaOH or 1 ml of 0.5M EDTA. The amount of
product, p-nitrophenol, was determined by measuring the absorbance at 405 nm. One unit of
protein phosphatase activity is defined as the amount of enzyme that hydrolyzes 1 nanomole of
PNPP in one minute at 30°C in a total reaction volume of 50 µl under standard reaction
conditions.
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CHAPTER 3: RESULTS AND DISCUSSION
CAD co-immunoprecipitates with Protein Phosphatase 1
Results obtained from western blot analysis after immunoprecipitation indicated that
CAD co-immunoprecipitates with PP1 as shown in Figure 17. The bands in lane 2 and lane 4
indicate the presence of CAD in the supernatant of BHK cells. Immunoprecipitation of PP1
using PP1-specific antibodies contained CAD indicating that CAD forms a complex with PP1
(lane 3 and lane 5).

Figure 17. Co-immunoprecipitation of CAD with PP1
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Pull Down Assay
Microcystin binds with PP1 and acts as its inhibitor. Microcystin pull down assays further
confirmed that CAD and PP1 form a complex. Microcystin agarose beads were used in the pull
down assays. No PP1 was pulled down with the control protein G agarose beads. PP1 pulled
down with the microcystin beads also revealed the presence of CAD indicating formation of a

Figure 18. Western Blot of the Microcystin pull-down assay
complex.
Protein Phosphatase Assay
As mentioned earlier, the PP1 binding site (PP1c) can bind either to a regulatory subunit
or to inhibitor proteins such as I-218. This can be demonstrated by measuring
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spectrophometrically the activity of PP1 with I-2 in presence of the WT peptide and two mutant
peptides at 405nm.
Also as discussed earlier, our hypothesis is that if the peptide binds to PP1, it should
block the inhibition of PP1 by its endogenous inhibitor, Inhibitor-2 (I-2). The WT peptide that
corresponds to the naturally occurring sequence in CAD (Wild-Type peptide: 444Gln-Gly-LeuAla-Asp-Lys-Val-Tyr-Phe-Leu-Pro-Lle-Thr-Pro-His-Tyr-Val460) was used for this assay.

µ M PNPP/30min

PP1 activity assay --WT peptide
1.2
1
0.8
0.6
0.4
0.2
0
Blank

I-2

Peptide

PP1

PP1 + I-2

PP1 + PP1 + I-2
Peptide + Peptide

Figure 19. PP1 activity with I-2 in the presence of the WT CAD peptide

As shown in Figure 19, PP1 by itself shows significant activity when it reacts with the
substrate PNPP and also shows similar activity in presence of only the WT peptide indicating
that the WT peptide binds to PP1 but does not inhibit its activity.
In the presence of only its endogenous inhibitor I-2, PP1 binds with I-2, I-2 inhibits the activity
of PP1 represented in the bar graph above encircled in red. However, a significant amount of
activity is recovered in presence of the WT peptide. These results suggest that I-2 is not able to
inhibit PP1 significantly indicating that the peptide maybe competing for the same binding site
on PPI.
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In the second assay, a mutant peptide in which Thr-456 is replaced by Alanine (Ala)
(Mutant peptide: 444Gln-Gly-Leu
Leu-Ala-Asp-Lys-Val-Tyr-Phe-Leu-Pro-Lle-Ala--Pro-His-TyrVal460) was used instead of the WT peptide. This peptide mimics non-phosphorylated
phosphorylated CAD
because Alanine
nine lacks the side chain that can be phosphorylated. The bar graph below (Figure
20) indicates similar activity of PP1 with its substrate, PNPP, as in the previous assay (Figure 19)
and the presence of the Ala mutant peptide does not significantly affect the activity of PP1.
PP1

Figure 20. PP1activity with I2 in the presence of the CAD (T456
(T456A)) peptide

The activity of PP1 was inhibited as expected in the presence of I-2 but in the presence of
the mutant peptide CAD (T456A)
(T456A), the ability of I-2 to inhibit PP1 is disrupted as indicated by
the bar graph encircled in red (Figure 20). The result of this assay indicates that the binding of
the WT CAD peptide and the Thr
Thr-456 Ala mutant peptide have the same affinity for PP1 and is
able to block the inhibition by I-2.
2.
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The result of the third assay was significant in terms of the second goal of the project
which is to determine if binding of the CAD peptides to PP1 depends on whether or not Thr-456
is phosphorylated. In this assay, the third mutant peptide was used in which Thr-456 was
replaced by Aspartate (Asp) which mimics phosphorylated CAD (Mutant peptide: 444Gln-GlyLeu-Ala-Asp-Lys-Val-Tyr-Phe-Leu-Pro-Lle-Asp-Pro-His-Tyr-Val460). As indicated by the bar
graph, the CADT456D peptide was largely ineffective against I-2. PP1 was inhibited by
Inhibitor-2 (I-2) clearly indicating that the interaction of Inhibitor-2 and PP1 is not disrupted in
presence of the Asp mutant peptide (Figure 21). Figure 22 summarizes the effect of the three
peptides.

µ M PNPP/30 min

PP1 activity assay Asp peptide
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
Blank

I-2

Peptide

PP1

PP1 + I-2

PP1 +
Peptide

PP1 + I-2
+ Peptide

Figure 21. PP1activity with I2 in the presence of the CAD (T456D) peptide
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Figure 22. PP1α activity-I2 vs. CAD peptide

An unanticipated result was that when the full length purified CAD protein was incubated
with PP1, the phosphatase activity increased more than 2-fold. The significance of this result is
not yet clear but it may be necessary mechanism to prevent premature phosphorylation of the
PKA phosphorylation site on CAD.
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CHAPTER 4: CONCLUSION
Results of the phosphatase assays provide evidence that the peptides, synthesized based
on the putative PP1 binding sequence in CAD, have the ability to affect the activity of inhibitor-2
(I-2) on PP1 as summarized in Figure 22.
The observation that the effect of the mutant CAD peptide, T456A, reduces the ability of
I-2 to inhibit PP1, and this peptide mimicked unphosphorylated wild type sequence, provides
support for the hypothesis that binding of the peptide to PP1 depends on unphosphorylated
Thr456 via the putative binding sequence, KVXF, of CAD.
The PP1 binding site on CAD is adjacent to the MAP kinase phosphorylation site. The
mutant peptide, Thr456D, which mimics phosphorylated CAD does not appear to hinder the
inhibitory effect of I-2, supporting the hypothesis that binding to PP1 depends on whether CAD
has been phosphorylated by MAP kinase on Thr456.
This project paves the way for future studies of the complex regulatory mechanisms of
CAD. The next step would be to investigate whether PKA binding alters the interactions of CAD
with PP1 and the phosphorylation state of Thr-456.
While the up- and down-regulation of the de novo pyrimidine pathway has been wellestablished, the understanding of the mechanism by which PP1 can affect CAD activity is the
unique contribution of this project. This project narrows down the region of CAD that interacts
with PP1 and suggests the possibility for the formation of a regulated complex. This project
begins to fill the gap in our understanding of how PP1 regulates CAD and ultimately the de novo
pyrimidine biosynthetic pathway and may serve in the design of drugs that could interrupt the
activation of this pathway in rapidly proliferating cells.
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